A total of 25 years after Eibl detected the first TP53 mutations in tumor probes from medulloblastomas [1], in 2016, the World Health Organization (WHO) introduced a revolutionary paradigm shift in the classification of these and other brain tumors. The gene discussed is TP53; the disease is medulloblastoma.